OrlandoMay 15 - 20DDW 2026San DiegoMay 16 - 20EASL Congress 2026
BarcelonaMay 27 - 30ASCO 2026ChicagoMay 29 - Jun 2EULAR 2026
ViennaJun 3 - 6EHA 2026
MilanJun 11 - 14BIO 2026San DiegoJun 16 - 19ENDO 2026BostonJun 18 - 21ADA 2026San FranciscoJun 19 - 22ESC 2026
LisbonAug 28 - Sep 1EASD 2026MadridSep 9 - 12ERS 2026
CopenhagenSep 12 - 15ESMO 2026
BerlinSep 12 - 16ECTRIMS 2026BarcelonaSep 17 - 20UEG Week 2026ViennaOct 3 - 7AHA 2026ChicagoNov 7 - 9ACR 2026Washington DCNov 14 - 19ASH 2026New OrleansDec 12 - 15AACR 2026ChicagoApr 24 - 29AAN 2026PhiladelphiaApr 25 - May 2ATS 2026OrlandoMay 15 - 20DDW 2026San DiegoMay 16 - 20EASL Congress 2026BarcelonaMay 27 - 30ASCO 2026ChicagoMay 29 - Jun 2EULAR 2026ViennaJun 3 - 6EHA 2026MilanJun 11 - 14BIO 2026San DiegoJun 16 - 19ENDO 2026BostonJun 18 - 21ADA 2026San FranciscoJun 19 - 22ESC 2026LisbonAug 28 - Sep 1EASD 2026MadridSep 9 - 12ERS 2026CopenhagenSep 12 - 15ESMO 2026BerlinSep 12 - 16ECTRIMS 2026BarcelonaSep 17 - 20UEG Week 2026ViennaOct 3 - 7AHA 2026ChicagoNov 7 - 9ACR 2026Washington DCNov 14 - 19ASH 2026New OrleansDec 12 - 15AACR 2026ChicagoApr 24 - 29AAN 2026PhiladelphiaApr 25 - May 2
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
Late-onset genetic cholestatic diseases are frequently missed in adults, leading to delayed diagnosis and suboptimal management. Increased awareness is critical.
PARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
New preclinical work links PARP1 deficiency to reduced amyloid burden and cognitive preservation in a familial Alzheimer's model.
Early Breast Cancer at ASCO 2026: Trials to Watch
ASCO 2026 is expected to bring pivotal data on adjuvant and neoadjuvant strategies in early breast cancer. Here is what clinicians should watch for.
Lower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?
New evidence examines whether reduced tirzepatide doses can maintain weight loss, with implications for long-term obesity management in primary care.
Few Pediatric Cancer Drugs Reach Phase 3 or Approval
The pipeline for pediatric oncology drugs remains sparse, with most candidates failing to progress beyond early-phase trials to approval.
Abdominal Obesity Linked to More Severe Menopause Symptoms
Women with central adiposity report more frequent and severe vasomotor and psychological menopause symptoms, with waist circumference emerging as a key clinical marker.
Hantavirus: Lethality, Transmission and What GPs Need to Know
Hantavirus carries case fatality rates up to 40% in some syndromes. Here is what clinicians and the public genuinely need to worry about.
SGLT2 Inhibitors and Ferroptosis: A New Mechanistic Picture in HF
Emerging evidence links SGLT2 inhibitors' cardiac benefit to ferroptosis suppression, offering a potential mechanistic explanation for their efficacy in heart failure.
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
EASL 2026: Alcohol Policy Action Needed for Liver Disease
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
EASL 2026: PSC Therapies Advance Beyond Symptom Management
EASL 2026 Forum: Enhancing Patient-Clinician Communication
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
HDV Management: EASL 2026 Highlights PegIFN-α as Standard
MASH Advanced Fibrosis: Experts Detail Unique Challenges at EASL 2026
MASH Diagnosis: Non-Invasive Markers Show Promise at EASL 2026
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
A-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
EASL 2026: Alcohol Policy Action Needed for Liver Disease
EASL 2026 Consensus: AATD-Liver Disease Management Standardised
Late-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
EASL 2026: PSC Therapies Advance Beyond Symptom Management
EASL 2026 Forum: Enhancing Patient-Clinician Communication
MASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
Variceal Bleeding Management: EASL 2026 Skills Centre Focuses on Endoscopic and Pharmacological Strategies
EASL 2026 Skills Learning Centre will address variceal bleeding, highlighting current evidence for endoscopic and pharmacological interventions.
EASL 2026: Liver and Spleen Elastography for Fibrosis Assessment
EASL 2026 will feature a Skills Learning Centre on liver and spleen elastography, highlighting its role in non-invasive fibrosis assessment.
EASL 2026 Forum: Enhancing Patient-Clinician Communication
The EASL 2026 Patient & Advocate Forum addresses critical gaps in patient-clinician communication and interprofessional collaboration.
EASL 2026: Alcohol Policy Action Needed for Liver Disease
3 min readA-TANGO Score Refines ACLF Diagnosis, Prognosis in Cirrhosis
3 min readMASLD Diagnosis Faces Barriers Despite 2024 EASL Guidelines
2 min readEASL 2026: Non-invasive Diagnostics Advance Liver Disease Staging
3 min readLate-Onset Genetic Cholestasis: Underdiagnosis in Adults Examined
3 min readHDV Management: EASL 2026 Highlights PegIFN-α as Standard
3 min readSGLT2 Inhibitors and Ferroptosis: A New Mechanistic Picture in HF
Emerging evidence links SGLT2 inhibitors' cardiac benefit to ferroptosis suppression, offering a potential mechanistic explanation for their efficacy in heart failure.
2025 AHA/ACC Hypertension Guidelines: What GPs Need Now
The 2025 AHA/ACC hypertension guidelines update prescribing priorities. Here is what the evidence says about antihypertensive management today.
PCSK9 Inhibitors Move Upstream: Evolocumab Tested in Diabetes Without Known Atherosclerosis
VESALIUS-CV tests evolocumab in diabetic patients without established atherosclerosis, while new trials probe plaque biology and lipid pathways beyond LDL.
SGLT2 Inhibitors Post-Heart Transplant: What the Data Show
3 min readAtrial Fibrillation and Cardio-Kidney-Metabolic Risk: A Systemic Challenge
2 min readAtrial Fibrillation Complexity: How Reliable is Registry Data?
3 min readTAVI and Aortic Dissection Risk: Is Valve Type a Factor?
3 min readSSEPs to Monitor Cerebral Perfusion During TCAR TAVR Procedures
2 min readLower-Dose Tirzepatide: Can It Sustain Weight Loss Long-Term?
New evidence examines whether reduced tirzepatide doses can maintain weight loss, with implications for long-term obesity management in primary care.
Oral Orforglipron Sustains Weight Loss After Injectable GLP-1 Therapy
The ATTAIN-MAINTAIN trial shows oral orforglipron preserves most injectable-achieved weight loss at 52 weeks, offering a scalable transition option.
GLP-1 Drugs and Oral Medication Absorption: What Prescribers Need to Know
GLP-1 receptor agonists slow gastric emptying, raising theoretical concerns about altered absorption of time-sensitive oral drugs. Evidence remains thin.
What Still Eludes Us in MASH Research?
3 min readLorlatinib and New-Onset Diabetes Practical Monitoring for Oncologists
3 min readLorlatinib and the Enigma of Autoantibody-Negative Diabetes
3 min readUnraveling MASH: Implications for Clinical Practice
2 min readSGLT2 Inhibitors: Promise and Peril in Prader-Willi Syndrome?
4 min readOpportunistic Osteoporosis Screening from CT Scans A Validated Approach?
4 min readPARP1 Deficiency Reduces Amyloid Pathology in Familial AD Model
New preclinical work links PARP1 deficiency to reduced amyloid burden and cognitive preservation in a familial Alzheimer's model.
Brain Cooling After Thrombectomy: Does Hypothermia Aid LVO Recovery?
Targeted temperature management after mechanical thrombectomy for LVO stroke is under active investigation, but the evidence base remains preliminary.
Gut Microbiota Signal the Brain via the Vagus Nerve: What GPs Should Know
The gut-brain axis operates partly through vagal afferent neurons. Here is what the established mechanistic evidence means for everyday practice.